Additionally, emerging evidence reveals that patients with detectable expression of Gal-3 in the tumor have more lymph node and distant metastases, frequent venous invasion and deeper wall invasion in comparison to Gal-3-negative cases [51]. This evidence concerns the gene LGALS3 and neoplasm.